[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647002":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":15,"collaborators":19,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":27,"acronym":10,"eligibilityCriteria":28,"healthyVolunteers":29,"sex":30,"minAge":31,"maxAge":10,"enrollmentInfo":32,"targetDuration":35,"studyType":36,"phases":10,"briefSummary":37,"conditions":38,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Training Set",null,"A cohort of ≥100 MM patients, 70 MGUS\u002FSMM patients (mixed at a 1:1 ratio), and 30 healthy controls will be used to train and construct the myeloma early screening model.",{"label":13,"type":10,"description":14,"interventionNames":10},"Validation Set","A cohort of 30 MM patients, 30 MGUS\u002FSMM patients (mixed at a 1:1 ratio), and 30 healthy controls will be used to validate the performance of the myeloma early screening model.",{"type":16,"investigatorFullName":17,"investigatorTitle":18,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Lei Fan","Chief Physician, Professor, Ph.D. Supervisor, Director of the Department of Hematology",[20],{"name":21,"class":22},"Nanjing Geneseeq Technology Inc.","INDUSTRY","100647002","early-screening-for-multiple-myeloma-based-on-liquid-biopsy-cfdna-fragmentomics-100647002",false,"NCT07684274","Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics","Inclusion Criteria:\n\n* Age over 40 years.\n* Diagnosed with MM, SMM, or MGUS through standard diagnostic procedures.\n* Voluntarily participating and signed written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Prior cancer diagnosis within the past 5 years, or history of any form of systemic cancer therapy (including chemotherapy, targeted therapy, immunotherapy, etc.).\n* History of organ transplantation, or allogeneic bone marrow or stem cell transplantation.\n* History of blood transfusion within 7 days prior to blood collection.\n* Poor compliance or potential interference with signing informed consent as judged by the investigator, or any other conditions rendering the subject unsuitable for the study.",true,"ALL","40 Years",{"count":33,"type":34},290,"ESTIMATED","5 Years","OBSERVATIONAL","Study on Early Screening of Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Technology. This study aims to construct and validate a set of machine learning models for the early screening of myeloma tailored to the Chinese population, based on plasma cfDNA fragmentomics features, to effectively distinguish myeloma patients from healthy individuals.",[39,40,41],"Multiple Myeloma (MM)","Smoldering Multiple Myeloma (SMM)","MGUS","NOT_YET_RECRUITING","2026-07-01",{"date":45,"type":46},"2026-07-06","ACTUAL",{"date":48,"type":34},"2026-06-13",{"date":50,"type":34},"2027-12-31",{"name":5,"class":6}]